应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
ABBV 艾伯维公司
盘前交易 09-19 05:30:41 EDT
192.94
-0.51
-0.26%
盘前
193.98
+1.04
+0.54%
05:18 EDT
最高
195.58
最低
191.78
成交量
323.68万
今开
193.13
昨收
193.45
日振幅
1.97%
总市值
3,408亿
流通市值
3,401亿
总股本
17.66亿
成交额
6.26亿
换手率
0.18%
流通股本
17.63亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
福鹏程：艾伯维将继续投资中国市场 加速新药和新适应症引入
中国新闻网 · 12:19
福鹏程：艾伯维将继续投资中国市场 加速新药和新适应症引入
头部药企再涉诉，这一次它如何应对？
投资时报 · 09-18 14:50
头部药企再涉诉，这一次它如何应对？
据彭博新闻社报导，诺和诺德称 Ozempic "极有可能 "进入 2027 年医疗保险谈判名单
Reuters · 09-18 07:13
据彭博新闻社报导，诺和诺德称 Ozempic "极有可能 "进入 2027 年医疗保险谈判名单
艾伯维下跌1.22%，报193.34美元/股
金融界 · 09-17 23:44
艾伯维下跌1.22%，报193.34美元/股
BUZZ-Leerink Partners 将药物开发商 Oruka 评为 "跑赢大盘"。
Reuters · 09-17 22:46
BUZZ-Leerink Partners 将药物开发商 Oruka 评为 "跑赢大盘"。
Ripple Therapeutics宣布与艾伯维公司达成合作和许可选择协议，共同开发下一代青光眼治疗方案
Accesswire · 09-17 20:30
Ripple Therapeutics宣布与艾伯维公司达成合作和许可选择协议，共同开发下一代青光眼治疗方案
BUZZ-古根海姆称辉瑞在ESMO上发布的中期抗癌药物数据 "引人入胜
Reuters · 09-16 19:15
BUZZ-古根海姆称辉瑞在ESMO上发布的中期抗癌药物数据 "引人入胜
美股三大指数开盘涨跌不一 Moderna跌近15%
腾讯自选股 · 09-12
美股三大指数开盘涨跌不一 Moderna跌近15%
百济神州(BGNE)盘前跌超6% 遭艾伯维(ABBV)再次起诉 称百济神州剽窃其BTK降解剂
金吾财讯 · 09-12
百济神州(BGNE)盘前跌超6% 遭艾伯维(ABBV)再次起诉 称百济神州剽窃其BTK降解剂
快问｜百济神州回应被艾伯维起诉
中新经纬 · 09-12
快问｜百济神州回应被艾伯维起诉
被艾伯维指责涉嫌窃取商业机密！百济神州回应：自身研发项目符合诚信原则，将坚决辩护
21世纪经济报道 · 09-12
被艾伯维指责涉嫌窃取商业机密！百济神州回应：自身研发项目符合诚信原则，将坚决辩护
盘前异动 | 百济神州跌超6%，再遭艾伯维起诉剽窃商业机密
老虎资讯综合 · 09-12
盘前异动 | 百济神州跌超6%，再遭艾伯维起诉剽窃商业机密
再遭艾伯维诉讼？百济神州AH股双双大跌
读创客户端 · 09-12
再遭艾伯维诉讼？百济神州AH股双双大跌
百济神州再遭美国药企诉讼，涉嫌窃取商业秘密
知产财经 · 09-12
百济神州再遭美国药企诉讼，涉嫌窃取商业秘密
美国 FDA 将 J&J 公司的银屑病药物扩展至炎症性肠病领域
Reuters · 09-12
美国 FDA 将 J&J 公司的银屑病药物扩展至炎症性肠病领域
巴尔的摩在预定的阿片类药物审判前与 Teva 和 Walgreens 达成和解
Reuters · 09-11
巴尔的摩在预定的阿片类药物审判前与 Teva 和 Walgreens 达成和解
艾伯维下跌1.22%，报194.02美元/股
金融界 · 09-11
艾伯维下跌1.22%，报194.02美元/股
艾伯维下跌1.25%，报194.54美元/股
金融界 · 09-05
艾伯维下跌1.25%，报194.54美元/股
艾伯维上涨1.26%，报198.782美元/股
金融界 · 09-03
艾伯维上涨1.26%，报198.782美元/股
健康巡讲：研究人员发现子宫内膜异位症与严重的心脏问题有关
Reuters · 08-30
健康巡讲：研究人员发现子宫内膜异位症与严重的心脏问题有关
加载更多
公司概况
公司名称：
艾伯维公司
所属市场：
NYSE
上市日期：
--
主营业务：
艾伯维公司注册成立于2012年4月10日，是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法，来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域，包括类风湿性关节炎，牛皮癣和克罗恩病，银屑病和克罗恩病;低睾酮，HIV，子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。
发行价格：
--
{"stockData":{"symbol":"ABBV","market":"US","secType":"STK","nameCN":"艾伯维公司","latestPrice":192.94,"timestamp":1726689600000,"preClose":193.45,"halted":0,"volume":3236828,"hourTrading":{"tag":"盘前","latestPrice":193.98,"preClose":192.94,"latestTime":"05:18 EDT","volume":173,"amount":33535.69016,"timestamp":1726737484032},"delay":0,"floatShares":1762884360,"shares":1766343745,"eps":2.98998,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.51,"latestTime":"09-19 05:30:41 EDT","open":193.13,"high":195.58,"low":191.7776,"amount":626499679.6125201,"amplitude":0.019656,"askPrice":195.62,"askSize":4,"bidPrice":193.91,"bidSize":4,"shortable":3,"etf":0,"ttmEps":2.98998,"exchange":"NYSE","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1726752600000},"adr":0,"adjPreClose":192.94,"adrRate":0,"dividendRate":0.031772,"preHourTrading":{"tag":"盘前","latestPrice":193.98,"preClose":192.94,"latestTime":"05:18 EDT","volume":173,"amount":33535.69016,"timestamp":1726737484032},"postHourTrading":{"tag":"盘后","latestPrice":192.94,"preClose":192.94,"latestTime":"19:59 EDT","volume":137812,"amount":26591080.6455,"timestamp":1726703970690},"volumeRatio":0.8718604496854544,"impliedVol":0.2651,"impliedVolPercentile":0.8406},"requestUrl":"/m/hq/s/ABBV","defaultTab":"news","newsList":[{"id":"2468051671","title":"福鹏程：艾伯维将继续投资中国市场 加速新药和新适应症引入","url":"https://stock-news.laohu8.com/highlight/detail?id=2468051671","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468051671?lang=zh_cn&edition=full","pubTime":"2024-09-19 12:19","pubTimestamp":1726719540,"startTime":"0","endTime":"0","summary":"艾伯维计划到2030年在中国市场推出40多种新产品和适应症。据悉，9月18日，艾伯维“中国合作日”首次线下活动在上海举行。此前，艾伯维“中国合作日”活动已连续举办三届线上活动。“艾伯维将继续在中国市场进行投资，推动免疫学、肿瘤学和眼科等核心产品的增长，积极推进创新产品管线，加速新药和新适应症的引入，提高治疗标准，扩大患者的用药可及性，以满足未被满足的医疗需求。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409191230229f06d270&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409191230229f06d270&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0795875169.SGD","LU0310799852.SGD","LU0256863811.USD","BK4533","LU1057294990.SGD","LU0820561909.HKD","LU0114720955.EUR","IE0002141913.USD","LU0198837287.USD","IE0009355771.USD","IE00B42XCP33.USD","LU0943347566.SGD","YINN","BK4534","LU0211328371.USD","LU0211327993.USD","LU0820561818.USD","LU0170899867.USD","LU0661504455.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU1093756168.USD","LU0689472784.USD","IE00B3PB1722.GBP","IE00BGHQF631.EUR","IE00BJJMRZ35.SGD","LU0203345920.USD","LU1093756325.SGD","LU1023059063.AUD","LU1003077747.HKD","BK4139","BK4581","BK4588","IE00BVYPNW00.USD","LU0882574055.USD","LU0128525929.USD","IE00BVYPNV92.GBP","ABBV","BK4559","LU0203347892.USD","LU0553294199.USD","LU0310800379.SGD","IE00B4R5TH58.HKD","LU1244550221.USD","IE0004445239.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU0456855351.SGD","LU1061106388.HKD","LU0708994859.HKD"],"gpt_icon":0},{"id":"2468912378","title":"头部药企再涉诉，这一次它如何应对？","url":"https://stock-news.laohu8.com/highlight/detail?id=2468912378","media":"投资时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468912378?lang=zh_cn&edition=full","pubTime":"2024-09-18 14:50","pubTimestamp":1726642251,"startTime":"0","endTime":"0","summary":"CDE官网显示，这是该款产品首次在国内申报临床。艾伯维称，目前百济神州已向美国食品药品监督管理局申请并获得了BTK降解剂BGB-16673的快速通道资格，进一步侵犯了艾伯维的商业秘密权。针对上述消息，百济神州方面向标点财经、投资时间网研究员称，公司否认这一指控，将对艾伯维发起的指控开展坚决辩护，坚决捍卫自身知识产权。该公司称，公司目前在仔细核阅艾伯维的控诉，并将通过法律程序做出适当回应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240918145137956c2b7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240918145137956c2b7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4505","CDE","BK4548","688235","BK4139","06160","BK4526","BK4585","BGNE","BK4504","BK4017","ABBV","BK4535"],"gpt_icon":0},{"id":"2468197923","title":"据彭博新闻社报导，诺和诺德称 Ozempic \"极有可能 \"进入 2027 年医疗保险谈判名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2468197923","media":"Reuters","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468197923?lang=zh_cn&edition=full","pubTime":"2024-09-18 07:13","pubTimestamp":1726614809,"startTime":"0","endTime":"0","summary":" 路透9月17日 - 据彭博新闻社周二援引一位公司高管的话报导，丹麦制药商诺和诺德 预计其糖尿病药物Ozempic \"极有可能 \"被列入美国政府2027年的价格谈判名单 。2022年《通胀削减法》的部分条款允许联邦医疗保险对价格特别昂贵的处方药进行价格谈判 ，该联邦医疗保险覆盖了数百万65岁及以上的美国人和残疾人。诺和诺德的高管此前曾表示，现在要知道谈判对Ozempic的影响还为时过早。华尔街分析师还押注于2027年上市的 ，其中将包括Ozempic。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","IE00BVYPNW00.USD","BK4585","LU0225284248.USD","SG9999002224.SGD","LU0170899867.USD","LU0820561909.HKD","NVO","LU1066053197.SGD","LU0234570918.USD","LU0306807586.USD","LU0256863902.USD","LU1003077747.HKD","LU1093756325.SGD","BK4139","LU0943347566.SGD","BK4588","LU0211328371.USD","LU0795875169.SGD","LU0985481810.HKD","LU0203345920.USD","LU1883839398.USD","LU0553294199.USD","LU1244550221.USD","LU0820561818.USD","IE00B19Z3581.USD","LU0114720955.EUR","LU0198837287.USD","BK4581","IE0002141913.USD","LU0456855351.SGD","LU0985320562.USD","IE00BVYPNV92.GBP","IE00BKVL7J92.USD","SG9999002232.USD","IE00B4R5TH58.HKD","ABBV","IE0009355771.USD","IE00B2B36J28.USD","LU0310800379.SGD","SG9999011175.SGD","LU0795875086.SGD","LU0689472784.USD","BK4592","SG9999003800.SGD","LU0310799852.SGD","IE00BSNM7G36.USD","IE00BFTCPJ56.SGD","BK4568"],"gpt_icon":0},{"id":"2468697283","title":"艾伯维下跌1.22%，报193.34美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2468697283","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468697283?lang=zh_cn&edition=full","pubTime":"2024-09-17 23:44","pubTimestamp":1726587891,"startTime":"0","endTime":"0","summary":"9月17日，艾伯维(ABBV)盘中下跌1.22%，截至23:44，报193.34美元/股，成交1.8亿美元。财务数据显示，截至2024年06月30日，艾伯维收入总额267.72亿美元，同比增长2.61%；归母净利润27.39亿美元，同比增长21.03%。大事提醒：10月25日，艾伯维将披露2024财年三季报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/09/17234443313633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0553294199.USD","IE0009355771.USD","LU0943347566.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0310799852.SGD","LU0114720955.EUR","LU0029864427.USD","LU0211328371.USD","BK4550","LU1061106388.HKD","LU0689472784.USD","IE0004445239.USD","LU0820561818.USD","IE00B2B36J28.USD","IE00BVYPNV92.GBP","LU1244550221.USD","LU0708994859.HKD","LU1003077747.HKD","LU0170899867.USD","LU0198837287.USD","LU1093756325.SGD","BK4139","LU0795875169.SGD","LU0985320562.USD","LU0949170772.SGD","LU0211327993.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4559","IE00BVYPNW00.USD","LU0234570918.USD","BK4585","BK4566","LU0128525929.USD","LU0882574055.USD","LU0203347892.USD","BK4588","LU0122379950.USD","LU0203345920.USD","LU0795875086.SGD","LU0820561909.HKD","LU0256863902.USD","ABBV","IE00BDGV0183.EUR","BK4581","IE00BSNM7G36.USD","LU0456855351.SGD","LU0310800379.SGD","LU0256863811.USD"],"gpt_icon":0},{"id":"2468363829","title":"BUZZ-Leerink Partners 将药物开发商 Oruka 评为 \"跑赢大盘\"。","url":"https://stock-news.laohu8.com/highlight/detail?id=2468363829","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468363829?lang=zh_cn&edition=full","pubTime":"2024-09-17 22:46","pubTimestamp":1726584385,"startTime":"0","endTime":"0","summary":" 9月17日 - ** Oruka Therapeutics ORKA.O> 股价上涨 4.87% 至 27.18 美元** 券商Leerink Partners开始对Oruka Therapeutics进行评级，评级为 \"跑赢大盘\"，目标价44美元。** 公司将于 2025 年第一季度开始 ORKA-001 的早期试验，用于治疗银屑病--一种会导致皮肤发炎和鳞屑的慢性自身免疫性疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0122379950.USD","LU0949170772.SGD","LU0211327993.USD","BK4139","BK4581","LU0158827948.USD","LU0689472784.USD","BK4533","LU0738911758.USD","LU0985320562.USD","LU0128525929.USD","LU1023059063.AUD","IE00BDGV0183.EUR","IE00B4R5TH58.HKD","LU0882574055.USD","IE00BVYPNV92.GBP","LU0198837287.USD","ORKA","LU1093756325.SGD","LU0234572021.USD","LU0256863902.USD","LU0661504455.SGD","LU0310799852.SGD","LU1244550221.USD","BK4585","LU0203347892.USD","LU0170899867.USD","ABBV","IE0004445239.USD","LU0708994859.HKD","LU0553294199.USD","LU0795875086.SGD","LU0456855351.SGD","LU0545039389.USD","LU1003077747.HKD","BK4534","BK4588","IE00B2B36J28.USD","LU0114720955.EUR","LU1061106388.HKD","LU0203345920.USD","IE0009355771.USD","LU0029864427.USD","LU0820561909.HKD","LU0912757837.SGD","LU0310800379.SGD","LU0211328371.USD","LU0234570918.USD","LU0820561818.USD"],"gpt_icon":0},{"id":"2468351882","title":"Ripple Therapeutics宣布与艾伯维公司达成合作和许可选择协议，共同开发下一代青光眼治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2468351882","media":"Accesswire","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468351882?lang=zh_cn&edition=full","pubTime":"2024-09-17 20:30","pubTimestamp":1726576200,"startTime":"0","endTime":"0","summary":"- Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/us/2024-09-17/doc-incpnmtk8649188.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/us/2024-09-17/doc-incpnmtk8649188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B42XCP33.USD","IE00BDGV0183.EUR","LU0912757837.SGD","LU0661504455.SGD","LU0310800379.SGD","LENZ","LU0256863902.USD","BK4581","LU0949170772.SGD","BK4588","LU0553294199.USD","LU0689472784.USD","LU0820561818.USD","IE00BGHQF631.EUR","LU0234572021.USD","IE00BVYPNW00.USD","LU0198837287.USD","IE00B2B36J28.USD","IE00BVYPNV92.GBP","LU0943347566.SGD","LU0795875169.SGD","LU0882574055.USD","LU0203347892.USD","LU1057294990.SGD","IE0009355771.USD","LU0820561909.HKD","LU0211327993.USD","LU1061106388.HKD","LU0545039389.USD","IE00BJJMRZ35.SGD","LU0417517546.SGD","BK4533","BK4139","LU0256863811.USD","IE00BJT1NW94.SGD","LU0211328371.USD","LU1093756168.USD","LU0114720955.EUR","LU0128525929.USD","BK4559","IE00BSNM7G36.USD","LU0738911758.USD","LU0234570918.USD","BK4585","LU1023059063.AUD","LU0456855351.SGD","ABBV","LU1244550221.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2467061816","title":"BUZZ-古根海姆称辉瑞在ESMO上发布的中期抗癌药物数据 \"引人入胜","url":"https://stock-news.laohu8.com/highlight/detail?id=2467061816","media":"Reuters","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467061816?lang=zh_cn&edition=full","pubTime":"2024-09-16 19:15","pubTimestamp":1726485344,"startTime":"0","endTime":"0","summary":" 9月16日 - ** 券商Guggenheim指出，辉瑞公司 的ponsegromab治疗癌症恶病质的中期数据 \"引人入胜\"；并表示，在预计于明年公布治疗心力衰竭的中期数据之前，投资者的兴趣可能会增加。** PFE 在欧洲肿瘤内科学会 上公布了该实验药物的数据，结果显示癌症恶病质患者的体重与安慰剂相比有所增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203345920.USD","LU0985320562.USD","LU1506573853.SGD","LU0256863902.USD","JNJ","LU0306807586.USD","IE00B7SZLL34.SGD","LU1934455194.USD","LU1917777945.USD","LU0114720955.EUR","LU0306806265.USD","PFE","BK4588","IE00B2B36J28.USD","LU0545039389.USD","LU0070302665.USD","LU0310800379.SGD","LU1032955483.USD","LU1934455277.USD","IE0002141913.USD","LU1037948897.HKD","IE00B4R5TH58.HKD","LU0198837287.USD","LU0266013472.USD","LU1066053197.SGD","LU0985481810.HKD","BK4592","LU0640476718.USD","LU1430594728.SGD","ABBV","LU0889566641.SGD","LU1196500208.SGD","LU0170899867.USD","LU1221951046.USD","LU1059921491.USD","BK4139","BMY","LU1941712264.USD","LU0265550946.USD","LU1883839398.USD","LU0949170772.SGD","BK4504","LU0029864427.USD","LU0225284248.USD","MRK","LU0310799852.SGD","LU2242652126.USD","LU0738911758.USD","LU0106261372.USD","LU1221951129.SGD"],"gpt_icon":0},{"id":"2466203377","title":"美股三大指数开盘涨跌不一 Moderna跌近15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2466203377","media":"腾讯自选股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466203377?lang=zh_cn&edition=full","pubTime":"2024-09-12 21:31","pubTimestamp":1726147878,"startTime":"0","endTime":"0","summary":"美股三大指数开盘涨跌不一，道指跌0.02%，纳指涨0.05%。百济神州开盘跌近6%，其回应遭艾伯维再次起诉：否认指控，将开展坚决辩护； Moderna跌近15%，2025年销售额预期令市场失望。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240912212818a1d9ed87&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240912212818a1d9ed87&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABBV","BIDU","BK1161","688235","06160","LU2328871848.SGD","MRNA","BK1588","LU0588546209.SGD","BGNE","BK1500","LU0307460666.USD","BK1583","LU1969619763.USD"],"gpt_icon":1},{"id":"2466226357","title":"百济神州(BGNE)盘前跌超6% 遭艾伯维(ABBV)再次起诉 称百济神州剽窃其BTK降解剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2466226357","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466226357?lang=zh_cn&edition=full","pubTime":"2024-09-12 17:12","pubTimestamp":1726132337,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州(BGNE)盘前跌超6%，截至发稿，报197.49美元。消息面上，据媒体，跨国药企艾伯维(ABBV)近期再次起诉了百济神州。理由是百济神州剽窃了其BTK降解剂（BTK degrader）的商业秘密。百济神州方面则表示，已获悉艾伯维近期向本公司提起一项诉讼，诉讼包含百济神州自主发现的化合物BGB-16673。百济神州将对艾伯维发起的指控开展坚决辩护，公司目前在仔细核阅艾伯维的控诉，并将通过法律程序做出适当回应。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/MTI5MjQwNzE0NzY0NzE5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MTI5MjQwNzE0NzY0NzE5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"279833","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU0882574055.USD","BK4139","LU2328871848.SGD","LU0198837287.USD","LU0170899867.USD","BK4588","BK4550","LU0820561909.HKD","LU1244550221.USD","IE0009355771.USD","LU0211328371.USD","LU0553294199.USD","LU0256863811.USD","LU1003077747.HKD","LU0310799852.SGD","IE00BVYPNW00.USD","LU1061106388.HKD","LU1093756325.SGD","BK4566","BK4559","LU0203345920.USD","IE00B2B36J28.USD","LU0943347566.SGD","LU0211327993.USD","BK4585","BGNE","LU0122379950.USD","LU0310800379.SGD","LU0307460666.USD","688235","BK1500","LU0114720955.EUR","IE00BJJMRZ35.SGD","BK4535","BK1588","LU0689472784.USD","BK1161","ABBV","IE00B4R5TH58.HKD","IE0004445239.USD","LU0588546209.SGD","LU0795875169.SGD","IE00BVYPNV92.GBP","IE0002141913.USD","LU0128525929.USD","LU0820561818.USD","LU0708994859.HKD","BK0239","06160"],"gpt_icon":0},{"id":"2466224123","title":"快问｜百济神州回应被艾伯维起诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2466224123","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466224123?lang=zh_cn&edition=full","pubTime":"2024-09-12 17:08","pubTimestamp":1726132105,"startTime":"0","endTime":"0","summary":"对此，百济神州工作人员12日回应中新经纬称，百济神州将对艾伯维发起的指控开展坚决辩护。百济神州称，目前在仔细核阅艾伯维的控诉，并将通过法律程序做出适当回应。艾伯维称，目前百济神州已向美国食品药品监督管理局申请并获得了BTK降解剂BGB-16673的快速通道资格，进一步侵犯了艾伯维的商业秘密权。2023年6月，艾伯维旗下公司Pharmacyclics指控百济神州的泽布替尼侵犯艾伯维伊布替尼专利，并在美国地方法院提起诉讼。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409121809339ef7a138&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409121809339ef7a138&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BGNE","ABBV","06160","BK0239"],"gpt_icon":0},{"id":"2466258432","title":"被艾伯维指责涉嫌窃取商业机密！百济神州回应：自身研发项目符合诚信原则，将坚决辩护","url":"https://stock-news.laohu8.com/highlight/detail?id=2466258432","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466258432?lang=zh_cn&edition=full","pubTime":"2024-09-12 17:04","pubTimestamp":1726131840,"startTime":"0","endTime":"0","summary":"有市场消息称，制药巨头艾伯维向百济神州提起一项诉讼，声称百济神州盗用其商业机密用于布鲁顿氏酪氨酸激酶降解剂项目。对此，百济神州回应南财快讯记者称，“公司将对艾伯维发起的指控开展坚决辩护。”百济神州表示，该诉讼意图阻碍BGB-16673的开发进程，BGB-16673是目前临床开发中进展最快的BTK降解剂。百济神州还表示，将聚焦推进BGB-16673开发项目，不会因此项诉讼而中断。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409121705449ef76c12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409121705449ef76c12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABBV","BK4504","BK4548","BK4588","BK4585","BK4535","688235","BK4139","06160","BGNE","BK4505","BK4526"],"gpt_icon":0},{"id":"1112729261","title":"盘前异动 | 百济神州跌超6%，再遭艾伯维起诉剽窃商业机密","url":"https://stock-news.laohu8.com/highlight/detail?id=1112729261","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112729261?lang=zh_cn&edition=full","pubTime":"2024-09-12 16:50","pubTimestamp":1726131038,"startTime":"0","endTime":"0","summary":"本周四（9月12日）， $百济神州(BGNE)$ 盘前跌超6%，截至发稿报197.49美元，跌幅6.47%：据海外医药行业媒体Fierce Biotech报道，跨国药企 $艾伯维公司(ABBV)$ （AbbVie）近期再次起诉了百济神州，理由是后者剽窃了其BTK降解剂（BTK degrader）的商业秘密。百济神州方面则表示，已获悉艾伯维近期向本公司提起一项诉讼，诉讼包含百济神州自主发现的化合物BGB-16673。百济神州将对艾伯维发起的指控开展坚决辩护，公司目前在仔细核阅艾伯维的控诉，并将通过法律程序做出适当回应。","market":"us","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BGNE","ABBV"],"gpt_icon":0},{"id":"2466472246","title":"再遭艾伯维诉讼？百济神州AH股双双大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2466472246","media":"读创客户端","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466472246?lang=zh_cn&edition=full","pubTime":"2024-09-12 14:49","pubTimestamp":1726123747,"startTime":"0","endTime":"0","summary":"截至记者发稿时，百济神州A股大跌10%，H股下跌6%。尽管大跌，但百济神州三季度表现依然抢眼，H股三季度至今大涨36%，A股大涨25%。有外媒称，上周五艾伯维诉讼百济神州，指控其窃取商业机密，涉及的项目是BTK CDAC。艾伯维提到其前雇员涉嫌窃取艾伯维 BTK降解剂的商业机密和机密信息，将这些信息披露给百济神州，并最终使用这些信息。百济神州的声明称艾伯维的诉讼是“为了阻碍”百济神州竞争性BTK降解剂BGB-16673的开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240912145427955f5556&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240912145427955f5556&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1003077747.HKD","LU0114720955.EUR","LU1244550221.USD","LU1061106388.HKD","LU0545039389.USD","LU0211328371.USD","LU0553294199.USD","IE00BGHQF631.EUR","LU0912757837.SGD","688235","LU0029864427.USD","BK4535","IE00B3PB1722.GBP","LU0256863811.USD","LU0417517546.SGD","LU0234572021.USD","LU0738911758.USD","BK4533","LU0234570918.USD","LU0795875169.SGD","LU0943347566.SGD","LU0795875086.SGD","IE0004445239.USD","06160","BK4566","BK4534","BGNE","LU0708994859.HKD","IE00BJJMRZ35.SGD","LU0661504455.SGD","LU1093756325.SGD","BK4548","BK4559","LU0122379950.USD","LU0310800379.SGD","IE00B42XCP33.USD","ABBV","LU1093756168.USD","IE00BSNM7G36.USD","LU0158827948.USD","BK4550","LU0882574055.USD","LU0203347892.USD","LU0310799852.SGD","IE0002141913.USD","LU0949170772.SGD","IE00BJT1NW94.SGD","LU1023059063.AUD","LU1057294990.SGD","LU0211327993.USD","LU0128525929.USD","IE00BDGV0183.EUR"],"gpt_icon":0},{"id":"2466216852","title":"百济神州再遭美国药企诉讼，涉嫌窃取商业秘密","url":"https://stock-news.laohu8.com/highlight/detail?id=2466216852","media":"知产财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466216852?lang=zh_cn&edition=full","pubTime":"2024-09-12 11:33","pubTimestamp":1726111996,"startTime":"0","endTime":"0","summary":"百济神州“引诱并鼓励”艾伯维前科学家刘华清利用其前雇主的商业秘密“推进和加速”百济神州的BTK降解剂项目。刘华清从艾伯维退休后，于2019年9月起在百济神州工作。在该诉讼中，刘华清亦被列为被告。百济神州在周一的声明中否认了艾伯维的指控，并表示“公司将在这起诉讼中坚决捍卫我们的知识产权”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240912113218ab633c56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240912113218ab633c56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ABBV","LU0122379950.USD","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","LU0234572021.USD","BK4504","LU1061106388.HKD","BGNE","688235","LU1244550221.USD","BK4550","LU0943347566.SGD","IE0002141913.USD","LU0795875086.SGD","BK4548","LU1023059063.AUD","LU0198837287.USD","IE00BJJMRZ35.SGD","LU0553294199.USD","LU0820561818.USD","LU1057294990.SGD","LU0203347892.USD","BK4585","IE00B4R5TH58.HKD","IE00BVYPNV92.GBP","LU0029864427.USD","BK4588","LU0456855351.SGD","BK4139","LU1003077747.HKD","LU0795875169.SGD","IE00BVYPNW00.USD","LU0114720955.EUR","IE00B2B36J28.USD","LU0256863811.USD","LU1093756325.SGD","LU0417517546.SGD","IE0009355771.USD","LU0211328371.USD","LU0203345920.USD","BK4534","LU0689472784.USD","LU0170899867.USD","BK4566","BK4581","BK4526","LU0256863902.USD","LU0882574055.USD","LU0985320562.USD","LU0158827948.USD","BK4505","06160"],"gpt_icon":0},{"id":"2466269253","title":"美国 FDA 将 J&J 公司的银屑病药物扩展至炎症性肠病领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2466269253","media":"Reuters","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466269253?lang=zh_cn&edition=full","pubTime":"2024-09-12 06:21","pubTimestamp":1726093263,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) 路透9月11日 - 强生公司周三表示，美国食品和药物管理局已允许扩大强生公司 药品Tremfya 的使用范围， 用于治疗一种慢性炎症性肠病的成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4592","ABBV","LU0211327993.USD","LU1267930730.SGD","IE00BFTCPJ56.SGD","IE00B1BXHZ80.USD","JNJ","LU1221951046.USD","GB00BDT5M118.USD","LU1061106388.HKD","BK4550","IE0002141913.USD","BK4533","BK4516","LU0820561818.USD","LU1506573853.SGD","LU1059921491.USD","IE00BJT1NW94.SGD","IE00BVYPNV92.GBP","LU0820561909.HKD","LU1551013342.USD","LU0079474960.USD","BK4139","LU1003077747.HKD","IE00B19Z3B42.SGD","IE00BVYPNW00.USD","BK4007","LU0114720955.EUR","IE000M9KFDE8.USD","IE00B2B36J28.USD","LU0310800379.SGD","LU0640476718.USD","IE0009355771.USD","LU0097036916.USD","LU1035775433.USD","LU1093756325.SGD","LU1196500208.SGD","LU0211328371.USD","LU0310799852.SGD","LU1430594728.SGD","IE0004445239.USD","LU1221951129.SGD","BK4568","LU0689472784.USD","BK4559","LU0170899867.USD","LU0889566641.SGD","BK4566","LU0985320562.USD"],"gpt_icon":1},{"id":"2466749641","title":"巴尔的摩在预定的阿片类药物审判前与 Teva 和 Walgreens 达成和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2466749641","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466749641?lang=zh_cn&edition=full","pubTime":"2024-09-11 04:21","pubTimestamp":1725999698,"startTime":"0","endTime":"0","summary":"就在该市与制药商Teva Pharmaceutical 就阿片类药物达成8000万美元和解协议的前一天，巴尔的摩市宣布了这一消息。巴尔的摩没有透露与沃尔格林的和解条款，但累计和解金额意味着也是8000万美元。巴尔的摩市今年早些时候宣布与制药商艾伯维 的Allergan部门、药房运营商CVS 和药品分销商Cardinal Health 达成和解。巴尔的摩市表示，例如，根据与 Teva 达成的多州和解协议，该市在 13 年内只能获得 1100 万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417517546.SGD","LU1023059063.AUD","MCK","BK4581","LU1430594728.SGD","IE00BZ1G4Q59.USD","SGXZ23171101.USD","ABBV","LU1037948897.HKD","IE00B19Z3581.USD","LU1585245621.USD","LU0289739699.SGD","LU1032955483.USD","JNJ","LU0320765646.SGD","LU1084165304.USD","CVS","LU0861579265.USD","LU1119994496.HKD","LU0949170772.SGD","LU1059921491.USD","LU0965508806.USD","LU1699723380.USD","LU0234572021.USD","LU0738911758.USD","LU0965509010.AUD","LU1037948541.HKD","LU0792757196.USD","LU0868494617.USD","LU1057294990.SGD","LU1261432733.SGD","LU1093756168.USD","WBA","BK4504","LU0985320562.USD","LU2468319806.SGD","LU1280957306.USD","LU0234570918.USD","IE0034235303.USD","CAH","IE00BSNM7G36.USD","LU0256863902.USD","COR","LU0072461881.USD","LU0661504455.SGD","IE00BJT1NW94.SGD","LU1196500208.SGD","IE00B1BXHZ80.USD","LU0965509101.SGD","LU1032466523.USD"],"gpt_icon":0},{"id":"2466465260","title":"艾伯维下跌1.22%，报194.02美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2466465260","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466465260?lang=zh_cn&edition=full","pubTime":"2024-09-11 00:22","pubTimestamp":1725985366,"startTime":"0","endTime":"0","summary":"9月11日，艾伯维(ABBV)盘中下跌1.22%，截至00:22，报194.02美元/股，成交3.31亿美元。财务数据显示，截至2024年06月30日，艾伯维收入总额267.72亿美元，同比增长2.61%；归母净利润27.39亿美元，同比增长21.03%。大事提醒：9月6日，艾伯维2024季度分配每1股派1.55美元股息，除权除息日2024-10-15，派息日2024-11-15。10月25日，艾伯维将披露2024财年三季报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/09/11002243167080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4139","BK4533","LU0310800379.SGD","IE00BFTCPJ56.SGD","ABBV","IE0002141913.USD","IE00B2B36J28.USD","LU0256863902.USD","LU0795875169.SGD","LU0949170772.SGD","LU0912757837.SGD","IE00B4R5TH58.HKD","LU0256863811.USD","IE0009355771.USD","BK4585","LU0985320562.USD","BK4534","IE00BDGV0183.EUR","LU0417517546.SGD","LU1244550221.USD","LU1003077747.HKD","LU0795875086.SGD","LU0820561818.USD","LU0114720955.EUR","LU0029864427.USD","IE00BVYPNV92.GBP","IE00BJJMRZ35.SGD","LU0234572021.USD","LU0820561909.HKD","LU1093756325.SGD","IE00BVYPNW00.USD","LU0170899867.USD","BK4588","LU0456855351.SGD","LU0882574055.USD","LU1061106388.HKD","LU0158827948.USD","LU0128525929.USD","LU0211328371.USD","LU0203345920.USD","LU0708994859.HKD","LU0234570918.USD","LU0738911758.USD","BK4581","LU0545039389.USD","LU0553294199.USD","IE00BSNM7G36.USD","LU0943347566.SGD","LU0310799852.SGD","LU1093756168.USD"],"gpt_icon":0},{"id":"2465528374","title":"艾伯维下跌1.25%，报194.54美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2465528374","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465528374?lang=zh_cn&edition=full","pubTime":"2024-09-05 22:13","pubTimestamp":1725545635,"startTime":"0","endTime":"0","summary":"9月5日，艾伯维(ABBV)盘中下跌1.25%，截至22:13，报194.54美元/股，成交9975.58万美元。财务数据显示，截至2024年06月30日，艾伯维收入总额267.72亿美元，同比增长2.61%；归母净利润27.39亿美元，同比增长21.03%。大事提醒：10月25日，艾伯维将披露2024财年三季报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/09/05221343066480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0122379950.USD","LU0203345920.USD","LU0158827948.USD","IE00BSNM7G36.USD","LU1093756325.SGD","BK4550","LU0689472784.USD","IE0004445239.USD","BK4566","LU0545039389.USD","LU1061106388.HKD","LU0882574055.USD","LU0943347566.SGD","LU1003077747.HKD","BK4533","IE00BJT1NW94.SGD","LU0310799852.SGD","LU0128525929.USD","LU0234572021.USD","LU0114720955.EUR","LU0203347892.USD","LU0708994859.HKD","LU0949170772.SGD","LU1244550221.USD","LU0912757837.SGD","LU0029864427.USD","LU1093756168.USD","LU0738911758.USD","LU1291159041.SGD","LU0795875169.SGD","BK4559","LU0553294199.USD","IE0009355771.USD","LU1057294990.SGD","IE00BJJMRZ35.SGD","LU0820561909.HKD","IE0002141913.USD","LU0661504455.SGD","LU0310800379.SGD","BK4585","BK4534","LU0211327993.USD","LU1244550577.SGD","LU1023059063.AUD","LU0417517546.SGD","LU0234570918.USD","LU0211328371.USD","ABBV","LU0256863811.USD","LU1267930573.SGD"],"gpt_icon":0},{"id":"2464802512","title":"艾伯维上涨1.26%，报198.782美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2464802512","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464802512?lang=zh_cn&edition=full","pubTime":"2024-09-03 21:57","pubTimestamp":1725371854,"startTime":"0","endTime":"0","summary":"9月3日，艾伯维(ABBV)盘中上涨1.26%，截至21:57，报198.782美元/股，成交6207.67万美元。财务数据显示，截至2024年06月30日，艾伯维收入总额267.72亿美元，同比增长2.61%；归母净利润27.39亿美元，同比增长21.03%。大事提醒：10月25日，艾伯维将披露2024财年三季报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/09/03215743012529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0158827948.USD","LU0882574055.USD","LU0029864427.USD","LU0795875086.SGD","BK4533","BK4550","LU0820561909.HKD","LU1244550221.USD","LU0211328371.USD","LU0203347892.USD","LU0912757837.SGD","IE00BSNM7G36.USD","LU0256863902.USD","LU0256863811.USD","LU0553294199.USD","LU0738911758.USD","BK4581","LU1003077747.HKD","LU1244550577.SGD","LU1267930573.SGD","LU0310799852.SGD","LU1093756325.SGD","LU1061106388.HKD","LU1057294990.SGD","LU0949170772.SGD","BK4566","LU0708994859.HKD","BK4559","LU0203345920.USD","LU1291159041.SGD","LU0417517546.SGD","LU0211327993.USD","LU0943347566.SGD","LU0122379950.USD","LU0310800379.SGD","LU0661504455.SGD","LU0114720955.EUR","IE00BJJMRZ35.SGD","BK4534","LU0234572021.USD","LU1023059063.AUD","LU0234570918.USD","ABBV","IE00BJT1NW94.SGD","IE0004445239.USD","LU0795875169.SGD","IE0002141913.USD","LU0128525929.USD","LU1093756168.USD","LU0545039389.USD"],"gpt_icon":0},{"id":"2463943142","title":"健康巡讲：研究人员发现子宫内膜异位症与严重的心脏问题有关","url":"https://stock-news.laohu8.com/highlight/detail?id=2463943142","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463943142?lang=zh_cn&edition=full","pubTime":"2024-08-30 03:25","pubTimestamp":1724959535,"startTime":"0","endTime":"0","summary":"今天，我们将报道有关常见疾病子宫内膜异位症与一系列严重心脏问题风险增加的研究结果。在长达 45 年的随访中，17.5% 的子宫内膜异位症妇女因动脉堵塞而心脏病发作或中风，而没有子宫内膜异位症的妇女只有 15.3%。患有子宫内膜异位症的妇女患心律问题和心力衰竭的风险也较高。这项研究并不能证明子宫内膜异位症是导致这些额外健康问题的原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU0708994859.HKD","LU0203345920.USD","LU0985320562.USD","BK4566","IE0004445239.USD","BK4585","IE00BJJMRZ35.SGD","LU0256863811.USD","LU1003077747.HKD","LU1244550494.USD","LU1061106388.HKD","LU0456855351.SGD","LU0689472784.USD","LU1267930490.SGD","BK4550","LU0114720955.EUR","LU0211327993.USD","BK4588","LU1057294990.SGD","IE00B2B36J28.USD","LU0882574055.USD","LU0203347892.USD","LU0310800379.SGD","LU0128525929.USD","LU1023059063.AUD","LU0553294199.USD","LU0820561818.USD","LU0820561909.HKD","IE0002141913.USD","BK4559","IE00B4R5TH58.HKD","BK4581","LU0198837287.USD","LU1244550221.USD","LU0795875169.SGD","LU1093756168.USD","LU1430594728.SGD","BK4533","ABBV","LU0943347566.SGD","LU0170899867.USD","LU1267930573.SGD","IE00BFTCPJ56.SGD","LU1093756325.SGD","LU0310799852.SGD","LU0122379950.USD","BK4139","IE00BJT1NW94.SGD","LU0211328371.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbvie.com","stockEarnings":[{"period":"1week","weight":-0.0085},{"period":"1month","weight":-0.02},{"period":"3month","weight":0.1209},{"period":"6month","weight":0.0812},{"period":"1year","weight":0.257},{"period":"ytd","weight":0.245}],"compareEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":0.0032},{"period":"3month","weight":0.0263},{"period":"6month","weight":0.0771},{"period":"1year","weight":0.2681},{"period":"ytd","weight":0.1811}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"艾伯维公司注册成立于2012年4月10日，是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法，来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域，包括类风湿性关节炎，牛皮癣和克罗恩病，银屑病和克罗恩病;低睾酮，HIV，子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.023334},{"month":2,"riseRate":0.833333,"avgChangeRate":0.030818},{"month":3,"riseRate":0.75,"avgChangeRate":0.006329},{"month":4,"riseRate":0.666667,"avgChangeRate":0.015725},{"month":5,"riseRate":0.666667,"avgChangeRate":0.006183},{"month":6,"riseRate":0.5,"avgChangeRate":0.00974},{"month":7,"riseRate":0.5,"avgChangeRate":0.01182},{"month":8,"riseRate":0.5,"avgChangeRate":-0.0014},{"month":9,"riseRate":0.416667,"avgChangeRate":0.005886},{"month":10,"riseRate":0.636364,"avgChangeRate":0.011149},{"month":11,"riseRate":0.818182,"avgChangeRate":0.080758},{"month":12,"riseRate":0.727273,"avgChangeRate":0.032678}],"exchange":"NYSE","name":"艾伯维公司","nameEN":"AbbVie"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾伯维公司,ABBV,艾伯维公司股票,艾伯维公司股票老虎,艾伯维公司股票老虎国际,艾伯维公司行情,艾伯维公司股票行情,艾伯维公司股价,艾伯维公司股市,艾伯维公司股票价格,艾伯维公司股票交易,艾伯维公司股票购买,艾伯维公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}